For research use only. Not for therapeutic Use.
Heclin is a HECT E3 ubiquitin ligases inhibitor. Heclin inhibits Smurf2, Nedd4, WWP1 (IC50 values are 6.8, 6.3, 6.9 μM) and can be used for the research of gastric cancer[1][2][3].
Heclin (10 μM, 1-5 days) inhibits cell viability and IGF1 signaling of BGC803 and MKN45 cell lines[1].
Heclin (7 μM, 1 h) ameliorates epinecidin-1-mediated MyD88 degradation in Raw264.7 cells[2].
| Catalog Number | I011195 |
| CAS Number | 890605-54-6 |
| Synonyms | (E)-N-(4-acetylphenyl)-3-(5-ethylfuran-2-yl)prop-2-enamide |
| Molecular Formula | C17H17NO3 |
| Purity | ≥95% |
| InChI | InChI=1S/C17H17NO3/c1-3-15-8-9-16(21-15)10-11-17(20)18-14-6-4-13(5-7-14)12(2)19/h4-11H,3H2,1-2H3,(H,18,20)/b11-10+ |
| InChIKey | SPTWXRJNCFIDRQ-ZHACJKMWSA-N |
| SMILES | CCC1=CC=C(O1)C=CC(=O)NC2=CC=C(C=C2)C(=O)C |
| Reference | [1]. Wang K, et al. Targeting the E3 ligase NEDD4 as a novel therapeutic strategy for IGF1 signal pathway-driven gastric cancer [J]. Oncogene, 2023, 42(14): 1072-1087. [2]. Su B C, Chen J Y. Antimicrobial peptide epinecidin-1 modulates MyD88 protein levels via the proteasome degradation pathway [J]. Marine Drugs, 2017, 15(11): 362. [3]. Mund T, et al. Peptide and small molecule inhibitors of HECT-type ubiquitin ligases [J]. Proceedings of the National Academy of Sciences, 2014, 111(47): 16736-16741. |
